|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nitrogen-carbon layer coated nickel nanoparticles for efficient electrocatalytic reduction of carbon dioxide显示文摘The application of nickel in electrocatalytic reduction of CO2 has been largely restricted by side reaction (hydrogen evolution reaction) and catalyst poisoning.Here we report a new strategy to improve the electrocatalytic performance of nickel for CO2 reduction by employing a nitrogen-carbon layer for nickel nanoparticles.Such a nickel electrocatalyst exhibits high Faradaic efficiency 97.5% at relatively low potential of-0.61 V for the conversion of CO2 to CO.Density functional theory calculation reveals that it is thermodynamically accomplishable for the reduction product CO to be removed from the catalyst surface,thus avoiding catalyst poisoning.Also,the catalyst renders hydrogen evolution reaction to be suppressed and hence reasonably improves catalytic performance. | Dongxing Tan Chaonan Cui Jinbiao Shi Zhixun Luo Bingxing Zhang Xiuniang Tan Buxing Han Lirong Zheng Jing Zhang Jianling Zhang | 2019 | Nano Research2019，12，5： | 3 |
| 2 | SynBioEcoli: a comprehensive metabolism network of engineered E. coil in three dimensional visualization显示文摘设计 E 的一个全面新陈代谢网络。coli 在系统生物学是很重要的, metabolomics 学习。许多工具集中于二维的空格在新陈代谢的网络显示小径。然而,三维的可视化的用法可以帮助更好理解新陈代谢、规章的网络的复杂拓扑学。方法我们手工地从文学的大量试验性的数据(包括的小径,反应和代谢物) 与设计 E 的不同类型联系了的 curated。coli 然后利用了三维的可视化的一种新奇技术开发一个全面新陈代谢的网络命名 SynBioEcoli。结果 SynBioEoli 包含 740 条 biosynthetic 小径, 3,889 新陈代谢的反应, 2,255 化学药品手工地从与设计 E 的不同类型联系的大约 11,000 份新陈代谢出版物加重 curated。coli。而且, SynBioEcoli 与各种各样的信息科学技术集成。结论 SynBioEcoli 能被认为是设计 E 的全面 knowledgebase。coli 并且代表下一代细胞的新陈代谢网络可视化技术。它能经由浏览器被存取(例如 Google 铬) 支持 WebGL,在 http://gffzz849681930f04473cho0qc9onxxkkn60f0.ffgz.tsg.suse.edu.cn/synbioecoli/ 。 | Weizhong Tu Shaozhen Ding Ling Wu Zhe Deng Hui Zhu Xiaotong Xu Chen Lin Chaonan Ye Minlu Han Mengna Zhao Juan Liu Zixin Deng Junni Chen Dong-Qing Wei Qian-Nan Hu | 2017 | Frontiers of Electrical and Electronic Engineering in China2017，5，1： | 2 |
| 3 | Co‑packaged optics(CPO):status,challenges,and solutions显示文摘Due to the rise of 5G,IoT,AI,and high-performance computing applications,datacenter trafc has grown at a compound annual growth rate of nearly 30%.Furthermore,nearly three-fourths of the datacenter trafc resides within datacenters.The conventional pluggable optics increases at a much slower rate than that of datacenter trafc.The gap between application requirements and the capability of conventional pluggable optics keeps increasing,a trend that is unsustainable.Copackaged optics(CPO)is a disruptive approach to increasing the interconnecting bandwidth density and energy efciency by dramatically shortening the electrical link length through advanced packaging and co-optimization of electronics and photonics.CPO is widely regarded as a promising solution for future datacenter interconnections,and silicon platform is the most promising platform for large-scale integration.Leading international companies(e.g.,Intel,Broadcom and IBM)have heavily investigated in CPO technology,an inter-disciplinary research feld that involves photonic devices,integrated circuits design,packaging,photonic device modeling,electronic-photonic co-simulation,applications,and standardization.This review aims to provide the readers a comprehensive overview of the state-of-the-art progress of CPO in silicon platform,identify the key challenges,and point out the potential solutions,hoping to encourage collaboration between diferent research felds to accelerate the development of CPO technology. | Min Tan Jiang Xu Siyang Liu Junbo Feng Hua Zhang Chaonan Yao Shixi Chen Hangyu Guo Gengshi Han Zhanhao Wen Bao Chen Yu He Xuqiang Zheng Da Ming Yaowen Tu Qiang Fu Nan Qi Dan Li Li Geng Song Wen Fenghe Yang Huimin He Fengman Liu Haiyun Xue Yuhang Wang Ciyuan Qiu Guangcan Mi Yanbo Li Tianhai Chang Mingche Lai Luo Zhang Qinfen Hao Mengyuan Qin | 2023 | Frontiers of Optoelectronics2023，16，1： | 1 |
| 4 | Immunotherapy resistance of lung cancer显示文摘In recent years,immunotherapy has made remarkable breakthroughs and brought long-term survival benefits to lung cancer patients.However,a high percentage of patients do not respond to immunotherapy or their responses are transient,indicating the existence of immune resistance.Current studies show that the interactions between cancer cells and immune system are continuous and dynamic.A range of cancer cell-autonomous characteristics,tumor microenvironment factors,and host-related influences account for heterogenous responses.Furthermore,with the identification of new targets of immunotherapy and the development of immune-based combinations,we propose the response strategies to overcome resistance. | Xin Yu Chaonan Han Chunxia Su | 2022 | Cancer Drug Resistance2022，5，1： | 1 |
| 5 | Favorable clinical outcomes of checkpoint inhibitorbased combinations after progression with immunotherapy in advanced non-small cell lung cancer显示文摘Aim:Immune checkpoint inhibitors(ICIs)have dramatically changed the treatment paradigm in patients with non-small-cell lung cancer(NSCLC).However,progression patterns with immunotherapy are currently unclear and therapeutic options beyond resistance remain challenging.Methods:We reviewed advanced NSCLC patients between January 2016 and December 2019 who were treated with anti-PD-1/PD-L1 inhibitors in our center and identified those who developed disease progression.Later-line treatment strategies were collected and objective response rate,progression-free survival(PFS),and overall survival(OS)were assessed.Results:Of the 118 patients,46(39.0%)showed oligoprogression and 72(61.0%)showed systemic progression.No difference in progression patterns was observed between monotherapy and combination therapy.Systemic progression was strongly associated with never-smokers(51.4%vs.21.7%,P=0.001)and ECOG PS=2(13.9%vs.2.2%,P=0.048)at baseline.The distribution of progression sites was roughly similar between oligoprogression and systemic progression,and the most commonly affected anatomic site was lung(66.9%),followed by bone(12.7%)and lymph nodes(11.0%).For patients beyond first disease progression,checkpoint inhibitor-based combinations could lead to a significantly longer PFS2 compared with ICIs monotherapy(9.63 months vs.4.23 months,P=0.004,HR=0.394,95%CI:0.174-0.893)and other therapy(9.63 months vs.4.07 months,P=0.046,HR=0.565,95%CI:0.326-0.980).Median OS of the ICIs combination group was not reached but was significantly longer than other therapy group(NR vs.14.37 months,P=0.010,HR=0.332,95%CI:0.167-0.661).Conclusion:Systemic progression occurs more frequently among NSCLC patients receiving ICIs.Checkpoint inhibitor-based combinations show favorable outcomes as subsequent treatment strategies after the failure of previous ICIs treatment. | Xin Yu Xiangling Chu Yan Wu Juan Zhou Jing Zhao Fei Zhou Chaonan Han Chunxia Su | 2021 | Cancer Drug Resistance2021，4，3： | 0 |
| 6 | A DFT study of CO_2 electrochemical reduction on Pb(211) and Sn(112)显示文摘Electrochemical reduction of CO2 has the benefit of turning greenhouse gas emissions into useful resources. We performed a comparative study of the electrochemical reduction of CO2 on stepped Pb(211) and Sn(112) surfaces based on the results of density functional theory slab calculations. We mapped out the potential energy profiles for electrochemical reduction of CO2 to formate and other possible products on both surfaces. Our results show that the first step is the formation of the adsorbed formate(HCOO*) species through an Eley-Rideal mechanism. The formate species can be reduced to HCOO- through a oneelectron reduction in basic solution, which produces formic acid as the predominant product. The respective potentials of forming HCOO* are predicted to be -0.72 and -0.58 V on Pb and Sn. Higher overpotentials make other reaction pathways accessible, leading to different products. On Sn(112), CO and CH4 can be generated at -0.65 V following formate formation. In contrast, the limiting potential to access alternative reaction channels on Pb(211) is -1.33 V, significantly higher than that of Sn. | Chaonan Cui Hua Wang Xinli Zhu Jinyu Han Qingfeng Ge | 2015 | Science China Chemistry2015，58，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员